search
Back to results

Brief Bactericidal Activity of Anti-Tuberculosis Drugs (BBA)

Primary Purpose

Tuberculosis, Drug-resistant Tuberculosis, Isoniazid Resistant Tuberculosis (Disorder)

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
High dose isoniazid
Sponsored by
Centers for Disease Control and Prevention
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tuberculosis

Eligibility Criteria

8 Years - 99 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent
  • INH resistance by approved molecular genetic test
  • Phenotypic drug susceptibility test results match one of the required patterns
  • Sputum microscopy positive for acid fast bacilli

Exclusion Criteria:

  • Ineligible for MDR TB treatment according to national guidelines
  • HIV infection with CD4 count less than 50
  • Pregnancy
  • Incarceration
  • Too sick to participate (Karnofsky score <60, arterial pO2<90, respiratory rate repeatedly >25/min, clinician's judgment)
  • Hepatic enzymes >3x normal
  • Estimated glomerular filtration rate <60 mL/min/1.73 m2
  • Unable to provide adequate sputum specimen

Sites / Locations

  • National Institute for Research on Tuberculosis

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

High dose isoniazid

Arm Description

INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing <45 kg)

Outcomes

Primary Outcome Measures

Delta CFU/ml/day
Change in colony forming units per ml of sputum over 6 days

Secondary Outcome Measures

Time-to-detection (TTD)
Interval in hours from culture inoculation to detection of mycobacterial growth in MGIT 960

Full Information

First Posted
September 8, 2014
Last Updated
October 13, 2020
Sponsor
Centers for Disease Control and Prevention
Collaborators
Kenya Medical Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02236078
Brief Title
Brief Bactericidal Activity of Anti-Tuberculosis Drugs
Acronym
BBA
Official Title
Brief Bactericidal Activity of Anti-Tuberculosis Drugs in Drug-Resistant Tuberculosis
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
November 2015 (undefined)
Primary Completion Date
September 30, 2020 (Actual)
Study Completion Date
September 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centers for Disease Control and Prevention
Collaborators
Kenya Medical Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators will determine the bactericidal activity of high-dose isoniazid against M. tuberculosis isolates that are (1) susceptible to isoniazid at 2.0 mcg/ml but resistant at 0.1 and 0.4 mcg/ml or (2) susceptible at 0.4 mcg/ml but resistant at 0.1 mcg/ml when tested in the BD MGIT 960 system. Further, the investigators will investigate the molecular genetic determinants of these differences in susceptibility. To achieve these objectives the investigators will carry out an innovative variation on early bactericidal activity (EBA) study methodology. Patients at risk for drug-resistant TB will be screened for INH resistance using approved molecular assays. In those with INH-resistant TB, the investigators will quickly perform phenotypic DSTs using the direct method in the Bactec Mycobacterium Growth Indicator Tube (MGIT) 960 system, so results will be available within 7 days. If the DST results show the susceptibility patterns noted above, patients will receive 900 mg/d INH (600 mg if <45kg), and assess its effect with serial quantitative sputum cultures for 6 days. If the concentration of viable bacteria decreases significantly, the investigators will interpret this to mean the drug is having an effect. If not, the drug is ineffective. After 6 days, the patients will resume treatment according to national guidelines. In case the investigators identify drugs that are effective under these conditions, the investigators will sequence known and putative genes associated with the action of these drugs for the mycobacterial isolates from these patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis, Drug-resistant Tuberculosis, Isoniazid Resistant Tuberculosis (Disorder)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High dose isoniazid
Arm Type
Experimental
Arm Description
INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing <45 kg)
Intervention Type
Drug
Intervention Name(s)
High dose isoniazid
Other Intervention Name(s)
High dose INH
Intervention Description
See arm description
Primary Outcome Measure Information:
Title
Delta CFU/ml/day
Description
Change in colony forming units per ml of sputum over 6 days
Time Frame
6 days
Secondary Outcome Measure Information:
Title
Time-to-detection (TTD)
Description
Interval in hours from culture inoculation to detection of mycobacterial growth in MGIT 960
Time Frame
6 days
Other Pre-specified Outcome Measures:
Title
Acquired isoniazid resistance
Description
Increased level of resistance to isoniazid
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent INH resistance by approved molecular genetic test Phenotypic drug susceptibility test results match one of the required patterns Sputum microscopy positive for acid fast bacilli Exclusion Criteria: Ineligible for MDR TB treatment according to national guidelines HIV infection with CD4 count less than 50 Pregnancy Incarceration Too sick to participate (Karnofsky score <60, arterial pO2<90, respiratory rate repeatedly >25/min, clinician's judgment) Hepatic enzymes >3x normal Estimated glomerular filtration rate <60 mL/min/1.73 m2 Unable to provide adequate sputum specimen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah E. Smith-Jeffcoat, MPH
Organizational Affiliation
U.S. Centers for Disease Control and Prevention
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
J. P. Cegielski, MD, MPH
Organizational Affiliation
JP Cegielski Consulting LLC
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institute for Research on Tuberculosis
City
Chennai
State/Province
Tamil Nadu
Country
India

12. IPD Sharing Statement

Citations:
PubMed Identifier
22938757
Citation
Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H; Global PETTS Investigators; Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012 Oct 20;380(9851):1406-17. doi: 10.1016/S0140-6736(12)60734-X. Epub 2012 Aug 30. Erratum In: Lancet. 2012 Oct 20;380(9851):1386.
Results Reference
background

Learn more about this trial

Brief Bactericidal Activity of Anti-Tuberculosis Drugs

We'll reach out to this number within 24 hrs